Thrombospondin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression by Po-Chun Chen et al.
RESEARCH Open Access
Thrombospondin-2 promotes prostate
cancer bone metastasis by the
up-regulation of matrix metalloproteinase-2
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Abstract
Background: Thrombospondin-2 (TSP-2) is a secreted matricellular glycoprotein that is found to mediate cell-to-
extracellular matrix attachment and participates in many physiological and pathological processes. The expression
profile of TSP-2 on tumors is controversial, and it up-regulates in some cancers, whereas it down-regulates in
others, suggesting that the functional role of TSP-2 on tumors is still uncertain.
Methods: The expression of TSP-2 on prostate cancer progression was determined in the tissue array by the
immunohistochemistry. The molecular mechanism of TSP-2 on prostate cancer (PCa) metastasis was investigated
through pharmaceutical inhibitors, siRNAs, and miRNAs analyses. The role of TSP-2 on PCa metastasis in vivo was
verified through xenograft in vivo imaging system.
Results: Based on the gene expression omnibus database and immunohistochemistry, we found that TSP-2
increased with the progression of PCa, especially in metastatic PCa and is correlated with the matrix
metalloproteinase-2 (MMP-2) expression. Additionally, through binding to CD36 and integrin ανβ3, TSP-2 increased
cell migration and MMP-2 expression. With inhibition of p38, ERK, and JNK, the TSP-2-induced cell migration and
MMP-2 expression were abolished, indicating that the TSP-2’s effect on PCa is MAPK dependent. Moreover, the
microRNA-376c (miR-376c) was significantly decreased by the TSP-2 treatment. Furthermore, the TSP-2-induced
MMP-2 expression and the subsequent cell motility were suppressed upon miR-376c mimic stimulation. On the
other hand, the animal studies revealed that the bone metastasis was abolished when TSP-2 was stably knocked
down in PCa cells.
Conclusions: Taken together, our results indicate that TSP-2 enhances the migration of PCa cells by increasing
MMP-2 expression through down-regulation of miR-376c expression. Therefore, TSP-2 may represent a promising
new target for treating PCa.
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Background
Prostate cancer (PCa) is one of the most frequently diag-
nosed cancers in men and is the second leading cause of
cancer deaths for men in the USA [1]. The majority of
deaths are due to the failures of diagnosis, current ther-
apies, and subsequent development of the metastatic
cancer, 80% of which is primarily metastasize to the
bone [2]. Thus, better strategies for the treatment of
PCa will ultimately require a better understanding of the
molecular mechanisms that trigger and drive cancer pro-
gression and metastatic processes.
Metastasis is a process that tumor cells leave a primary
location, travel through circulation, and form a second-
ary tumor in the distant organ. Bone metastasis is a
common complication associated with advanced cancers,
including PCa, often causing acute pain and bone frac-
tures, and the major reason for the cause of deaths in
patients [3]. The breakdown of the basement membrane
surrounding the tumors as well as the increase in the
abilities of proliferation, migration, and invasion are the
hallmarks of metastasis [4]. The well-studied protease
linked with migration and invasion is the matrix metal-
loproteases (MMPs). MMP-2 and MMP-9, also known
as gelatinases, play a key role for cleaving type I, IV col-
lagen and contribute to the process of metastasis [5]. In
PCa, MMP-2 and MMP-9 are considered useful prog-
nostic markers and are correlated to PCa progression
[6], indicating that the interaction between tumor cells
and extracellular matrix is associated with tumorigen-
esis. Thus, targeting the factors that can regulate the
activity of MMPs may develop as a strategy to suppress
PCa progression.
Thrombospondin (TSP), a glycoprotein that belongs to
a group of matricellular proteins, participates in cell-to-
cell and cell-to-matrix communication [7]. The human
TSP protein family consists of five members, named
TSP-1~5 [8]. TSP-1 and TSP-2 are highly expressed dur-
ing the tissue remodeling that is associated with cancer
progression, whereas the roles of the other members of
TSPs in tissue remodeling are less well understood. The
structure of TSP-1 and TSP-2 is similar, but their ex-
pression patterns are temporally and spatially different
during mouse development, suggesting that they may
play different roles [7–9]. In response to injury, the ex-
pression of TSP-2 is increased and is associated with
tumor growth [8]. In addition, TSP-2 might play a role
in collagen fibrillogenesis in the skin and tendons, sug-
gesting that TSP-2 modulates the cell surface properties
of mesenchymal cells, and thus, regulates cell functions,
such as adhesion and migration [10]. Through binding
to CD36 with their type I repeats, TSP-1 and TSP-2 have
been reported to serve as an anti-angiogenic molecule
[11]. Additionally, the arginine-glycine-aspartic acid
(RGD) sequence in TSP-2 has been reported that it
binds to integrin ανβ3 and heparan sulfate proteoglycans
which are associated with cell adhesion or binds to the
low-density lipoprotein receptor-related protein (LRP)
that modulates the concentration of TSP-2 in the peri-
cellular environment by endocytosis and lysosomal deg-
radation of the protein [12]. Through interaction with
LRP, TSP-2 binds to pro-MMP-2 and MMP-2 that regu-
lates the extracellular levels of MMP-2 which is import-
ant for controlling several physiological processes, such
as collagen fibrillogenesis, wound healing, and angiogen-
esis [13, 14]. Moreover, TSP-1, TSP-2 was also demon-
strated to play roles on anti-angiogenesis in the tumors
[11, 15]. However, the expression profile of TSP-2 is
quite controversial, which is down-regulated in cervical
cancer [9] and ovarian cancer [16], while it is overex-
pressed in oral cavity squamous cell carcinoma [17], pul-
monary adenocarcinoma [18], and prostate cancer [19],
suggesting that TSP-2 may play another role rather than
anti-angiogenesis. These studies indicate that the role of
TSP-2 on tumorigenesis is still controversial, especially
on metastasis.
MicroRNAs (miRNAs) are small non-coding RNA that
regulates gene expression through binding to 3′ untrans-
lated region (3′UTR) of mRNA, which with important
functions in development, cell differentiation, regulation
of cell cycle, and apoptosis [20, 21]. Through up- or
down-regulation of tumor suppressor genes, miRNAs
may function in either an oncogenic or tumor suppres-
sor role and they appear to play important and unique
roles with respect to PCa progression [22]. Several miR-
NAs have been illustrated to mediate metastasis, includ-
ing miR-154, miR-376c, miR-377, miR-381, and miR-495
[23]. It has been shown that miR-376c enhances prolifer-
ation, survival, and chemo-resistance by targeting activin
receptor-like kinase 7 in ovarian cancer [24]. Whereas,
others showed that miR-376c inhibit cell proliferation
and invasion by targeting the transforming growth
factor-α in osteosarcoma [25]. Thus, miR-376c may play
“dual” roles on tumor progression. However, its role on
PCa cells is largely uncertain. Herein, we showed for the
first time that TSP-2 up-regulates MMP-2 expression
and the subsequent cell motility in human PCa cells.
Furthermore, these TSP-2’s effects are dependent on
down-regulation of miR-376c expression.
Methods
Reagents
Recombinant human TSP-2 was purchased from R&D
Systems (Minneapolis, MN, USA). The anti-rabbit TSP-
2 was obtained from Abnova (Taipei, Taiwan); anti-
rabbit p38, anti-mouse p-ERK, ERK, p-JNK, and p-p38
were obtained from Santa Cruz (CA, USA); anti-mouse
MMP-2 was from R&D Systems (MN, USA). The inhibi-
tors for p38 (SB203580), ERK (U0126), JNK (SP600125),
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and MMP-2 (MMP-2 inhibitor I) were purchased from
Calbiochem (San Diego, CA, USA). The inhibitors for in-
tegrin α4β1 (sulfo-N-succinimidyl oleate (SSO)), CD36
(BIO1221), integrin αvβ3 (RGD), and the control peptide
(RAD) were purchased from Torcis Bioscience (Ellisville,
MO, USA). The Luciferase assay kit was purchased from
Promega (Madison, WI, USA). TSP-2 shRNA plasmids
were purchased from National RNAi Core Facility Plat-
form (Taipei, Taiwan). The TSP-2 shRNA oligo sequences
were 5′-CCGGCCCTCCTAAGACAAGGAACATCTCG
AGATGTTCCTTGTCTTAGGAGGGTTTTTG-3′ which
target to the sequence of TSP-2 is 5′-CCCTCCTAAGA
CAAGGAACAT-3′. MiR-376c mimic was purchased
from Invitrogen (Carlsbad, CA, USA). All other chemicals
were purchased from Sigma-Aldrich (St. Louis, MO,
USA).
Microarray data
The TSP-2 gene expression profile data was retrieved
from the GEO database (http://www.ncbi.nlm.nih.gov/
geo/). A total of 182 normal prostate tissues, as well as
benign, primary, and metastatic prostate tumors were
obtained from the microarray data with the following ac-
cession numbers: GDS1439 and GDS2545. The TSP-2
gene expression profiles were retrieved from GEO data
analysis tools. Further analysis of TSP-2 gene expression
between normal, primary tumor, and metastatic tumor
were examined by one-way ANOVA with Bonferroni’s
multiple comparisons test and p value ≤0.05 showed
significance.
Cell culture
Human PCa cell lines (PC-3 and DU145) and human
normal prostate epithelial cell lines (PZ-HPV7) were ob-
tained from the American Type Culture Collection
(ATCC). PC-3 and DU145 cells were grown in RPMI-
1640 medium supplemented with 20 mM HEPES, 10%
heat-inactivated fetal calf serum, 2 mM glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin. PZ-
HPV7 cells were grown in keratinocyte-SFM, containing
bovine pituitary extract and recombinant epidermal
growth factor. All cells were maintained in a humidified
incubator at 37 °C, 5% CO2.
Transwell assay
The migration assay was performed using the transwell
plates (Costar, NY, USA). The invasion assay was per-
formed using the same transwell plate except for coating
Corning® Matrigel® Matrix (Corning, NY, USA) in the
lower chamber. Selection of invasive prostate cancer
cells (PC-3-I3 and DU145-I5) was performed by using
transwell invasion assay as described previously [26].
Briefly, the transwell inserts were coated with Matrigel,
prostate cancer cells were resuspended in 1% FBS
containing media and seeded into the wells in the upper
layer, with the lower layer supplied with 10% FBS con-
taining media. After 48 h, the inserts were removed, and
cells that had migrated through the membranes and
become attached to the lower chamber compartments
were trypsinized and expanded for second-round selec-
tion. The PC-3-I3 and DU145-I5 invasive prostate
cancer cells were established after 3 and 5 rounds of
selection, respectively.
Small interfering RNA (siRNA) transfection
Cells were transfected with siRNAs according to man-
ufacturers’ recommendations on standard procedure
[26, 27]. The siRNAs (ON-TARGETplus SMARTpool)
were purchased from GE Dharmacon (Lafayette, CO,
USA). Cells were transfected with siRNA using
Lipofectamine 2000 reagent. The mRNA knockdown
efficiency was confirmed by real-time PCR as
described in the following sections.
Reverse transcription (RT) and real-time PCR
Total RNA was extracted from PCa cells using a TRIzol
kit as described previously [26]. Briefly, the reverse tran-
scription reaction was performed using the oligo (dT)
primer. Real-time PCR analysis was carried out using
SYBR with sequence-specific primers. The GAPDH
mRNA expression was used as an internal control.
For miRNA detection, reverse transcription was per-
formed using Mir-X™ miRNA First-Strand Synthesis and
SYBR® RT-PCR with the specific forward primer of miR-
376c (5′-AACATAGAGGAAATTCCACGT-3′). The U6
snRNA was used for normalization. The threshold was
set above the non-template control background and
within the linear phase of target gene amplification to
calculate the cycle number at which the transcript was
detected (denoted as CT).
Immunoblotting assay
Protein was isolated from PCa cells, and its concentra-
tion was then determined as described previously [27].
Proteins were resolved by SDS-PAGE and transferred to
Immobilon polyvinylidene fluoride membranes. After
incubation with primary and secondary antibodies, the
membranes were visualized by enhanced chemilumines-
cence using Kodak X-OMAT LS film.
Zymography analysis
The supernatants of the indicated condition of cells were
mixed with sample buffer without reducing agent and
heating. The sample was performed with SDS-PAGE
containing gelatin (1 mg/ml). Afterwards, the gel was
washed with 2.5% Triton X-100 to remove SDS, rinsed
with 50 mM Tris–HCl, pH 7.5, and then incubated over-
night at room temperature with the developing buffer
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(50 mM Tris–HCl, pH 7.5, 5 mM CaCl2, 1 μM ZnCl2,
0.02% thimerosal, 1% Triton X-100). The zymographic
activities were revealed by staining with 1% Coomassie
blue. The same samples were performed with SDS-
PAGE without gelatin and staining with 1% Coomassie
blue as loading control.
Immunohistochemical (IHC) staining
The protein expression was determined on tissue slides
using IHC staining as described previously [26]. Human
PCa tissue array (T195b and PR956) was purchased from
Biomax (MD, USA) in the form of 5 μm sections of
paraffin-embedded tissue on glass slides. The tissue slides
were incubated with human TSP-2 and MMP-2 anti-
bodies, followed by counterstaining with hematoxylin.
Plasmid construction and luciferase activity assay
The 3′UTRs of the human MMP-2 gene were amplified by
PCR using the following primer: Forward primer, 5′-
GAGTTTAAACCCTCTTTAAGTCTGTTTCTTC-3′, Re-
verse primer, 5′-GCGCTAGCCAACTAATAATGGCCTT
TTT-3′. The 3′UTRs of MMP-2 were cloned downstream
of the reporter gene in the pGL2-Control vector. The pre-
dicted MMP-2 binding site for miRNA was identified by
the miRDB (http://mirdb.org/miRDB). Mutant plasmids
that attenuate the interaction between MMP-2 3′UTR and
miRNA were generated using a QuikChange Site-Directed
Mutagenesis kit (Stratagene, Cedar Creek, TX, USA). Muta-
genesis of miR-376c targeting seed region of MMP-2 3′
UTR were amplified by PCR using the following primers:
Forward primer, 5′-CAATTAATAGAGTGCTTTCTGGG
TGCAAGGCACTTTTCACG-3, Reverse primer, 5′-CGT
GAAAAGTGCCTTGCACCCAGAAAGCACTCTATTAA
TTG′-3”. These plasmids with 3′UTR of MMP-2 and β-
galactosidase as control were transfected into cells using
lipofectamine 2000. Following transfection, these cells were
incubated with the indicated agents. Cell extracts were pre-
pared and used for measuring the luciferase and β-
galactosidase activities as the manufacturer’s recommenda-
tions. Activities of luciferase and β-galactosidase were then
measured by Luciferase Assay System (Promega, WI, USA).
In vivo metastasis model
PC-3 constitutively expressed pLenti CMV V5-Luc cells
were transfected with TSP-2 shRNA plasmids and se-
lected by puromycin. PC-3 stable cells (2 × 106) which
containing control vector or TSP-2 shRNA-expressing
vector were intratibially injected with 200 μl Matrigel
into the right tibia of nude mice (4-week old). Bone me-
tastasis was monitored using an in vivo imaging system
(Xenogen IVIS imaging system). The mice were
humanely sacrificed after 4 weeks. The tumor mass was
removed from the right tibia bone to detect its weight.
Microcomputed tomography (micro-CT) analysis
After the mice were sacrificed, the tibia of tumor growth
were dissected and fixed in 4% paraformaldehyde for
micro-CT analysis. The tibia for micro-CT scanning was
assessed by using a micro-CT scanner (Skyscan 1176;
Bruker, Kontich, Belgium). Reconstruction of sections
was carried out with GPU-based scanner software (NRe-
con, Bruker). In addition, the grayscale was based on the
Hounsfield unit, and the validated calcium standards
were scanned as the density reference. The three-
dimensional microstructural volumes from the micro-
CT scans were analyzed using Skyscan software (CTAn,
Bruker). Bone volume was used to assess the bone
resorption area of the bone metastasis.
Meta-analyses of microarray datasets from The Cancer
Genome Atlas (TCGA) database
The 499 prostate adenocarcinoma datasets were re-
trieved from the TCGA. The datasets included mRNA,
microRNA expression levels, and clinical data. Total 50
paired adjacent normal and tumor specimens were used
to analyze expression level of TSP-2 and miR-376c. The
paired t test was performed, and p value ≤0.05 showed
significance. The TSP-2 and MMP-2 expression levels
were correlated with Gleason score of the tumor speci-
mens. The one-way ANOVA with Bonferroni’s multiple
comparisons test was performed, and p value ≤0.05
showed significance. The correlation between TSP-2 and
MMP-2 was analyzed by all mRNA sequencing results
in the dataset.
Statistical analysis
All data presented as mean ± standard error of the mean
(SEM). Statistical analysis between the two samples was
performed using the Student t test. p < 0.05 was consid-
ered significant.
Results
The expression of the TSP-2 is correlated with PCa
progression
The previous studies of TSP-2 in tumor progression are
still controversial. To examine the correlation and role
of TSP-2 in PCa progression, we therefore manipulated
the GEO database. The two independent datasets of PCa
were retrieved and analyzed, and we found that the ex-
pression of the TSP-2 gene was higher in PCa, especially
on metastatic tumors (Fig. 1a, b). Surprisingly, these re-
sults were not consistent with the previous investigation
[19]. To further confirm the TSP-2 expression levels on
PCa progression in vivo, the samples from the different
stages of PCa patients were collected. Enormous studies
have indicated the crucial roles of MMP-2 in PCa prog-
nostic significance progression [28, 29]. Therefore, we
assessed the correlation between TSP-2 and MMP-2
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expression in PCa specimens. The expressions of TSP-2
and MMP-2 in patients with PCa were higher than that
in normal individuals (Fig. 1c–e). Additionally, the ex-
pressions of TSP-2 and MMP-2 were positively
correlated and highly expressed in prostate-bone meta-
static compared to the localized tumor (Fig. 1d, e), indi-
cating that TSP-2 was associated with clinical pathologic
stages in PCa. Furthermore, the expression of MMP-2
Fig. 1 The expression of TSP-2 is correlated with MMP-2 expression and tumor stage in PCa. The THBS2 genes were searched from the
GEO database. a GDS1439 and b GDS2545 were detected by microarray, and the TSP-2 expression values were collected independently.
c TSP-2 and MMP-2 protein were determined in the tissue array by IHC staining using their specific antibodies. The sections were photographed, and
staining intensity was then scored from 0 to 5 based on their expression intensity. The expression of TSP-2 (d) and MMP-2 (e) were quantified by the
clinical pathologic stages (stage I and II for early stage, stage III and IV for late stage), and f the correlation between TSP-2 and MMP-2 were analyzed with
Pearson correlation. The one-way ANOVA with Bonferroni’s multiple comparisons test was performed and p≤ 0.05 showed significance. N normal, T tumor
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was positively correlated to TSP-2 (Fig. 1f ). Meanwhile,
we also showed that the expressions of TSP-2 and
MMP-2 as well as the migratory and invasive abilities
were higher in two human PCa cell lines, PC-3 and
DU145, than that in normal prostate epithelial PZ-HPV7
cells (Fig. 2a–c). MMP-2 is an established pro-migratory
protease that participates in cancer migration and inva-
sion, suggesting that TSP-2 regulates MMP-2 followed
by modulating migration and invasion in PCa cells. To
clarify this issue, highly migratory PC-3-I3 and DU145-
I5 cells were selected by transwell assay (Fig. 2d, e, and
g). These cells also showed higher MMP-2 and TSP-2
expressions than the PC-3 and DU145 cells (Fig. 2f, h).
Taken together, these results indicated that the expres-
sion of TSP-2 is associated with cell migration, invasion,
and PCa progression.
MMP-2 is involved in TSP-2-induced cell migration and
invasion in human PCa cells
To verify the migratory effect of TSP-2 on PCa cells,
PC-3 and DU145 cells were treated with various concen-
trations of TSP-2. Results showed that both migratory
and invasive activities significantly increased upon TSP-
2 treatment via a concentration-dependent manner
(Fig. 3a, b, and Additional file 1: Figure S3A). Mean-
while, the expressions of MMP-2 protein and mRNA as
well as the amount of active MMP-2 were also enhanced
by TSP-2 stimulation (Fig. 3c–e and Additional file 1:
Figure S1A and B). To clarify whether MMP-2 is in-
volved in the TSP-2-induced migration and invasion in
human PCa cells, MMP-2 inhibitors and siRNA were ap-
plied. As shown in Fig. 3f–i, either MMP-2 inhibitor or
siRNA (Additional file 1: Figure S2A and B) abolishes
the TSP-2-induced migration and invasion in PC-3 and
DU145 cells. These results revealed that the TSP-2-
augmented migration and invasion in PCa cells are
MMP-2 dependent.
The CD36 and integrin αvβ3 are involved in the
TSP-2-induced MMP-2 activation and the subsequent cell
motility in human PCa cells
Several membranous receptors, including CD36 [30], in-
tegrin α4β1 [31], and integrin αVβ3 [32], have been
shown to mediate the TSP-2’s physiological roles on can-
cers. To investigate which receptors are responsible for
mediating the TSP-2-induced MMP-2 activation and
migration in human PCa cells, chemical inhibitors for
those receptors were applied (Additional file 1: Figure
S4A and B). As shown in Fig. 4a, b, the TSP-2-induced
migration and invasion were significantly inhibited upon
BIO1221 and arginine-glycine-aspartic acid (RGD) pep-
tide, but not by arginine-alanine-aspartic acid (RAD)
control peptide or sulfo-N-succinimidyl oleate (SSO)
treatments. This indicated that the TSP-2-induced
migration and invasion is mediated through CD36 and
integrin αvβ3, but not by integrin α4β1. Moreover, inhib-
ition of CD36 showed the higher suppressing effects on
TSP-2-augmented cell motility than that by integrin
αvβ3. Meanwhile, these phenomena are similar to TSP-
2’s effects on MMP-2 mRNA, protein, and activity in
human PCa cells (Fig. 4c–e). These results suggested
that the TSP-2-induced MMP-2 activation, cell migra-
tion, and invasion are mainly mediated through CD36,
and partially through integrin αVβ3, but not integrin
α4β1 in human PCa cells.
TSP-2 promotes cell migration and MMP-2 expression via
the mitogen-activated protein kinase (MAPK) pathway in
human PCa cells
The MAPK is involved in several key signaling compo-
nents and phosphorylation events that play important
role in tumorigenesis, including migration and invasion
[33]. To determine whether the MAPK pathway partici-
pates in TSP-2-induced migration on PCa cells, p38,
ERK, and JNK signaling pathways were assessed. As
shown in Fig. 5a, either p38, ERK, or JNK were phos-
phorylated following TSP-2 stimulation. To further
study whether these MAPK signaling pathways were
involved in TSP-2-induced MMP-2 expression and mi-
gration, MAPK inhibitors and siRNA were used. The
mRNA and protein expressions of p38, ERK, and JNK
were abolished upon their specific siRNA transfection
(Additional file 1: Figure S2C and D). All these siRNAs
showed no inhibitory effects on cell migration and inva-
sion (Additional file 1: Figure S4C and D). Results
showed that the TSP-2-induced MMP-2 mRNA expres-
sion, migration, and invasion were abolished upon inhib-
ition of p38, ERK, and JNK pathways by using inhibitors
or siRNA (Fig. 5b–g). These results demonstrated that
TSP-2 induces cell migration and MMP-2 expression
through the MAPK-dependent pathway.
TSP-2 promotes cell migration and MMP-2 expression
through down-regulation of microRNA-376c in human
PCa cells
Previous studies have shown that microRNA (miRNA)
plays important roles on regulation of cancer progres-
sion and metastasis [20]. To investigate whether miRNA
is responsible for the TSP-2-induced MMP-2 expression,
nine predicted miRNAs that contain binding sites of the
3′UTR of MMP-2, identified by microRNA.org (http://
www.microrna.org/microrna/home.do), were studied.
Results showed that the expression of miR-376c was
mostly down-regulated following TSP-2 stimulation
(Fig. 6a) and via a dose-dependent manner (Fig. 6c and
Additional file 1: Figure S1C) in PC-3, DU145, and
LNCaP cells. To validate whether MMP-2 serves as a
target for miR-376c, MMP-2 protein expression was
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Fig. 2 (See legend on next page.)
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monitored following miR-376 mimic transfection. Re-
sults showed that MMP-2 protein expression was obvi-
ously decreased upon miR-376 mimic transfection in
DU145 and PC-3 cells (Fig. 6b), indicating that MMP-2
is a miR-376c target. To illustrate whether miR-376c is
involved in the TSP-2-induced MMP-2 expression and
migration, the synthesized miR-376c mimic was applied.
Results showed that the TSP-2-induced MMP-2 mRNA
expression, migration, and invasion were all abolished
upon miR-376c mimic transfection in PC-3 and DU145
cells (Fig. 6d–f ). To further confirm whether miR-376c
was specifically targeted to MMP-2, the luciferase re-
porter vectors harboring wild-type or mutant 3′UTR of
MMP-2 were constructed (Fig. 6g). These vectors were
transfected into PC-3 and DU145 cells followed by treat-
ment with TSP-2, and the luciferase activity was then
assessed. The luciferase activity was increased only in
wild-type MMP-2 3′UTR transfection, but not in mu-
tant MMP-2 3′UTR, and via a concentration-dependent
manner (Fig. 6g). Meanwhile, the TSP-2-augmented
MMP-2 luciferase activity was attenuated upon miR-
376c mimic transfection (Fig. 6h), indicating that the
TSP-2-induced MMP-2 expression is mediated by
down-regulating miR-376c expression.
To decipher the molecular mechanism of TSP-2’s ef-
fects on miR-376c, inhibitors of the membranous recep-
tors of TSP-2 were applied. Results showed that the
TSP-2-decreased miR-376c expression was reversed
upon the BIO1211 and RGD peptide, but not by SSO
stimulation (Fig. 6i), indicating that the receptors of
CD36 and integrin αVβ3, but not integrin α4β1, are re-
sponsible for the TSP-2-down-regulated miR-376c ex-
pression. To determine the intracellular signaling of the
TSP-2-down-regulated miR-376c, the MAPK pathways
were studied. Results showed that the TSP-2-reduced
miR-376c expression was rescued by treatment with
p38, ERK, or JNK inhibitors (Fig. 6j) or their siRNAs
(Fig. 6l). Interestingly, the miR-376c expression is sensi-
tive to the inhibition of p38, ERK, and JNK (Additional
file 1: Figure S4E and F), especially in the presence of
TSP-2 (Fig. 6j, l), suggesting that some TSP-2-
independent pathway may play roles on miR-376c regu-
lation. Meanwhile, the TSP-2-induced miR-376c binding
ability was also suppressed upon knockdown of p38,
ERK, and JNK signaling pathways (Fig. 6k, m). These re-
sults indicated that miR-376c was down-regulated by
TSP-2 via the CD36, integrin αvβ3, and MAPK-
dependent pathway in human PCa cells.
Knockdown of TSP-2 decreases PCa cell migration and
osteolytic metastasis in vivo
To confirm the role of TSP-2 in PCa metastasis in vivo,
we took advantage of PC-3 cells that stably express
pLenti CMV V5-Luc (PC-3/Luc) and transfected with
TSP-2 shRNAs. Results showed that the protein and
mRNA expressions of TSP-2 were significantly abolished
in stably expressing TSP-2 shRNA PC-3 cells (PC-3/
shTSP-2-Luc) (Fig. 7a, b). In addition, the migratory and
invasive abilities of PC-3/shTSP-2-Luc cells were obvi-
ously decreased compared to that in control cells (PC-3/
Luc) (Fig. 7c). Furthermore, the expression of miR-376c
in PC-3/shTSP-2-Luc cells was higher than that in PC-
3/Luc cells (Fig. 7d), indicating that miR-376c expression
is negatively correlated to TSP-2. Moreover, the prolifer-
ation rate between PC-3/Luc and PC-3/shTSP-2-Luc
cells was almost same (Fig. 7e), indicating that TSP-2
knockdown did not affect cell proliferation rate. Previous
studies have indicated the critical roles of MMP-2 in
bone metastasis in various tumors. MMP-2 expression is
contributed to matrix degradation and osteolytic bone
metastasis in many tumors such as prostate cancer [34],
breast cancer [35, 36], and renal cell carcinoma [37]. To
explore the role of TSP-2/MMP-2 axis in bone metasta-
sis of prostate cancer, we performed mouse models of
bone metastasis by intratibial injection of cancer cells,
and the bone metastasis was then detected by biolumin-
escence imaging. Our results showed that knockdown of
TSP-2 significantly inhibited PCa metastasis in vivo
(Fig. 7f, g). Moreover, the TSP-2 expression is positively
associated with MMP-2 expression in vivo, as demon-
strated by immunoblotting and IHC staining (Fig. 7j, k),
indicating that TSP-2 decreases MMP-2 expression and
the subsequent metastasis in vivo. On the other hand,
the metastatic tumor growth and osteolytic area were
significantly reduced in the TSP-2 knockdown group
(Fig. 7h, i, l, and m), suggesting that TSP-2 is essential
for tumor invasion in vivo. Taken together, the inhibition
of TSP-2 on PCa suppresses bone metastasis in vivo.
(See figure on previous page.)
Fig. 2 TSP-2 is highly expressed in metastatic human PCa cells. a Total proteins were extracted from PZ-HPV7, DU145, and PC-3 cells
and subjected to immunoblotting analysis using anti-MMP-2 and TSP-2 antibodies, and re-probed against β-actin to show equal loading
amounts. b The MMP-2 (open bar) and TSP-2 (closed bar) mRNA expressions of PZ-HPV7, DU145, and PC-3 cells were examined by
real-time PCR. c The migratory (open bar) and invasive (closed bar) abilities of PZ-HPV7, DU145, and PC-3 cells were determined by the
transwell assay. d Total protein was extracted from PC-3, PC-3-I3, DU145, and DU145-I5 cells and subjected to immunoblotting analysis
using anti-MMP-2 and TSP-2 antibodies. The MMP-2 and TSP-2 mRNA expression (f and h) as well as migration and invasion (e and g)
ability of PC-3, PC-3-I3, DU145, and DU145-I5 cells were determined by RT-PCR and the transwell assay, respectively. Results are expressed
as mean ± SEM. *p < 0.05 when compared to PZ-HPV-7, PC-3, or DU145 cells









Fig. 3 (See legend on next page.)
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Fig. 3 TSP-2 induces migration and invasion in human PCa cells. PC-3 (open bar) and DU145 (closed bar) cells were incubation with TSP-2 (10–100 ng/ml)
for 24 h, and their abilities of migration (a) and invasion (b) were measured by the transwell assay, and the MMP-2 protein and mRNA expressions as well
as its activity were analyzed through immunoblotting (c), real-time PCR (d), and zymography (e) analyses, respectively. PC-3 (open bar) and DU145 (closed
bar) cells were pretreated with vehicle control (DMSO) or 2 μM of MMP-2 inhibitor (f and g) for 30 min or transfected with MMP-2 siRNA (h and i), followed
by stimulation with or without TSP-2 for another 24 h, and then assessed their migratory (f and h) and invasive (g and i) abilities. Cells without treatments
were used as a control (set to 100), and data were shown as multiples of that. Results are shown as the mean ± SEM (n≥ 3). The one-way ANOVA with
Bonferroni’s multiple comparisons test was performed, and p≤ 0.05 showed significance. *p< 0.05 when compared to untreated control; #p< 0.05 when






Fig. 4 TSP-2-induced MMP-2 activation and migration were mediated through CD36 and integrin αvβ3 in human PCa cells. Starved PC-3 (open bar)
and DU145 (closed bar) cells were pretreated with SSO (500 and 5000 nM), RAD control peptide (200 nM), RGD peptide (200 nM), and BIO1211 (5 and
500 nM) for 1 h, followed by incubation of TSP-2 for another 24 h. The abilities of migration (a), invasion (b), as well as the expressions of MMP-2
protein (c), mRNA (d), and its activity (e) were assessed by the transwell assay, immunoblotting, real-time PCR, and zymography, respectively. Cells
without treatments were used as a control (set to 100), and data were shown as multiples of that. Results are shown as the mean ± SEM (n≥ 3,
*p < 0.05 when compared to untreated control; #p < 0.05 when compared to the TSP-2-treated group)







Fig. 5 TSP-2-induced migration was mediated through the MAPK-dependent pathway in human PCa cells. a Starved DU145 cells were incubated
with TSP-2 for 10, 15, 30, 60, and 120 min, and the phosphorylation of p38, ERK, and JNK were examined by immunoblotting using anti-phospho
p38, ERK, and JNK antibodies, and followed by re-probing against to total p38, ERK, JNK, and β-actin to show equal loading amounts. The DU145
cells were pretreated with the p38 inhibitor (SB203580), ERK inhibitor (U0126), and JNK inhibitor (SP600125) for 1 h (b, d, and e), transfected with
p38, ERK, and JNK siRNA (c, f, and g), and stimulated with TSP-2 for 24 h. The MMP-2 mRNA expression was measured by real-time PCR (b and c),
and the migratory (d and f) and invasive (e and g) abilities were assessed by the transwell analysis. Cells without treatments were used as a control
(set to 100), and data were shown as multiples of that. Results are shown as the mean ± SEM (n≥ 3, *p < 0.05 when compared to untreated control;
#p < 0.05 when compared to the TSP-2-treated group). UT untreated control
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The expressions of TSP-2 and MMP-2 are correlated with
the Gleason score of PCa
To further verify the roles of TSP-2 on PCa progression,
the correlation of TSP-2 and PCa progression was deter-
mined by The Cancer Genome Atlas (TCGA) database.
Results indicated that PCa patients show the higher TSP-2
expression level than those on health individuals (Fig. 8a).
Furthermore, the expression levels of TSP-2 and MMP-2
were increased with the Gleason score of PCa (Fig. 8c, d).
Meanwhile, the expression of TSP-2 is positively correlated
with MMP-2 (Fig. 8e). However, the expression of miR-
376c showed the slightly decreased in PCa tumor (Fig. 8b).
In summary, these results suggested that TSP-2 plays a
positive role on PCa progression.
Discussion
TSP-2 has been demonstrated to play an anti-angiogenic
role on tumor cells [11, 15]. However, its expression pro-
file is controversial, being down-regulated in some
tumors [9, 16], while being overexpressed in others
Fig. 6 TSP-2 promotes migration and MMP-2 expression by down-regulating microRNA-376c expression in human PCa cells. a Starved PC-3 and
DU145 cells were treated with or without 30 ng/ml of TSP-2 for 24 h, and the expressions of nine miRNAs which targets to MMP-2 3′UTR were
measured by real-time PCR in PC-3 (open bar) and DU145 (closed bar) cells. Results were shown as multiple of untreated control. b PC-3 and
DU145 cells were transfected with miR-376c mimic, and the MMP-2 protein expression was then determined by immunoblotting assay. c Starved
PC-3 and DU145 cells were treated with 10, 30, and 100 ng/ml of TSP-2 for 24 h, and miR376c expression was then assessed by real-time PCR.
The PC-3 and DU145 cells were transfected with miR-376c mimic, followed by treatment with TSP-2 for 24 h. MMP-2 mRNA expression (d), as
well as the abilities of migration (e) and invasion (f) were then assessed. g PC-3 and DU145 cells were transfected with wild-type or mutant 3′UTR
plasmid of MMP-2 containing a miR-376c binding site (upper row). The relative luciferase/renilla activities were then measured following 10, 30,
and 100 ng/ml of TSP-2 stimulation. h PC-3 and DU145 cells were co-transfected with miR-376c and plasmids harboring with wild-type or mutant
3′UTR of MMP-2, followed by stimulation of TSP-2 for 24 h. The relative luciferase/renilla activities were then measured. Starved PC-3 and DU145
were pretreated with (i) SSO (500 and 5000 nM), RAD control peptide (200 nM), RGD peptide (200 nM), and BIO1211 (5 and 500 nM), or (j and k)
SB203580, U0126, and SP600125 (2 μM) for 1 h, or (l and m) transfected with p38, ERK, and JNK siRNA, followed by incubation of TSP-2 for another
24 h. The miR-376c expression and the relative luciferase/renilla activities were then assessed. Cells without treatments were used as a
control (set to 1 or 100), and data were shown as multiples of that. Results are shown as the mean ± SEM (n≥ 3, *p < 0.05 when compared to
untreated control; #p < 0.05 when compared to the TSP-2-treated group). UT untreated control, WT wild type, MUT mutant
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[17–19]. Thus, the biological functions of TSP-2 are still
uncertain, especially in PCa. Our IHC results indicated
that TSP-2 expression was positively correlated with
PCa progression, and this result is consistent with the
TSP-2 expression pattern in the other datasets of PCa.
Moreover, the TCGA dataset of PCa consolidates our
finding in this study. The TSP-2 expression is higher in
PCa patients and correlated with tumor progression.
TSP-2 exhibit an extensive modular domains named
exosites, which have been implicated in interaction with
various cell surface, matrix, and proteolytic proteins.
Moreover, the properdin-like type 1 repeats (TSR) of
TSP-2 were found to interact with MMP-2 and endo-
cytosis of complexes by LRP. This mechanism reveals
the modulation of MMP-2 secretion from cells by TSP-2
expression [14]. Although TSP-2 binds to MMP-2 that
regulates the extracellular levels of MMP-2 during colla-
gen fibrillogenesis, wound healing, and angiogenesis
[13], little is known about the roles of TSP-2 on PCa
progression. To investigate the biological roles of TSP-2,
PCa cell lines, PC-3, DU145, and LNCaP were applied.
We revealed that TSP-2 induces MMP-2 expression and
the subsequent migration and invasion in PC-3, DU145,
and LNCaP cells. Moreover, the migratory ability of PC-
3 is significantly higher than that in DU145 cells. This
result is consistent to other studies showing the higher
motility in PC-3 cells [38]. It may have resulted from the
higher expression of TSP-2 in PC-3, thus inducing more
MMP-2 expression. Furthermore, the higher TSP-2 ex-
pression level showed the higher MMP-2 expression, mi-
gratory, and invasive abilities which were also observed
in PC-3-I3 and DU145-I5, compared to PC-3 and
Fig. 7 Knockdown of TSP-2 decreases cell migration and osteolytic metastasis in vivo. PC-3 constitutively expressed pLenti CMV V5-Luc cells
were a transfected scramble of (PC-3/Luc) or TSP-2 shRNA (PC-3/shTSP-2-Luc), followed by determining their TSP-2 protein (a), or mRNA (b), and
miR-376c (d) expressions by immunoblotting and real-time PCR, respectively. The migration (open bar), invasion (closed bar) (c), or cell viability (e)
were also determined by the transwell assay and MTT analysis, respectively. f These cells were injected into the right tibia bone of nude mice
and detection by bioluminescence imaging at the indicated time intervals, and (g) these images were quantified (photons/s of the right leg).
After 4 weeks, these mice were sacrificed, and the tumors were excised (h) and their weights were determined (i). The expressions of TSP-2 and
MMP-2 on these tumors were then assessed by immunoblotting (j) or IHC staining (k). l Represents the micro-CT images of the tibia from sacrifice
mice. Scale bar = 1 mm. m This represents quantification of the resorption area of the tibia. WT wild type, KD knockdown
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Fig. 8 (See legend on next page.)
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DU145, respectively. Meanwhile, the knockdown of
TSP-2 also suppressed the migratory and invasive abil-
ities in PC-3 cells through attenuating MMP-2 expres-
sion. These results confirmed the biological roles of
TSP-2 in human PCa cells. Furthermore, we also showed
that metastatic PCa has a higher TSP-2 and MMP-2 ex-
pression when compared with normal prostate tissue,
suggesting that TSP-2 might be associated with
advanced PCa. Moreover, bone metastasis is obviously
inhibited while TSP-2 is knocked down when compared
to wild-type mice in vivo. Taken together, these results
reveal that the TSP-2 expression level is associated with
tumor metastasis, suggesting that TSP-2 could be used
as a biomarker of PCa progression.
The development of an antiangiogenic target has been
a common strategy for cancer therapy for a long time,
but substantial benefits remain unrealized because
tumors elicit evasive resistance [39]. Interestingly, the
inhibition of VEGFR/PDGFR by applying their kinase
inhibitors sunitinib/SU11248 can accelerate metastatic
tumor growth and decrease overall survival in mice, but
cannot function as an anti-cancer strategy [40]. TSP-1
and TSP-2 were considered as an anti-cancer molecular
by inhibiting angiogenesis through antagonizing VEGF
expression or suppressing metastasis by manipulating
MMPs activity in several cancers, including PCa [41, 42].
Surprisingly, under hypoxia conditions, TSP-1 might
trigger cell migration in advanced PCa cells [43], sug-
gesting that the anti-angiogenic molecules may switch to
play a positive role for tumor cell migration. Herein, we
showed for the first time that the expression TSP-2 is
correlated to the PCa progression, especially on the
metastasis. Since, TSP-2 is the homology to TSP-1, we
considered that TSP-2 may share the similar mechanism
to TSP-1, showing the promotion of the migratory
effects on tumor progression. Further experiments are
needed for clarifying this issue in the future.
TSP-1 and TSP-2 have been known as the anti-
angiogenic molecules which may bind to CD36 [30, 41].
Interestingly, the inhibition between TSP-1 and CD36 by
the TSP1 antibody A4.1 blocks the TSP-1’s effects on
anti-angiogenesis [44] and also suppresses the migration
of C4-2 cells [43], suggesting that the CD36 is respon-
sible for the TSP-1-induced migration. This result is
similar to our study showing that CD36 participated
in the TSP-2-induced MMP-2 expression and the
subsequent migration and invasion. In addition to CD36,
TSP-2 also regulates angiogenesis and cell motility,
through integrins, including integrin α4β1 [31] and αVβ3
[32]. Integrins are a large family of cell-surface glycopro-
teins, which bind to several extracellular matrix compo-
nents and regulate cytoskeletal organization and
facilitate cell motility. Overexpression of integrin αVβ3
has been found in many cancers, including melanoma,
prostate, and breast cancer and is associated with their
malignancy and responsible for their bone metastasis
[45, 46]. Herein, we also showed for the first time that
the TSP-2’s effects on PCa cell migration and invasion
are mediated through integrin αVβ3, but not integrin
α4β1 in human PCa cells.
It has been shown that miRNAs are involved in mul-
tiple biological processes and are also tightly correlated
with tumor progression, including PCa [20]. The miR-
376c belongs to the miR-376 cluster gene family, con-
taining miR-376a, miR-376a*, and miR-376b. The
lower miR-376c level is correlated with a higher PSA
and Gleason score [10], suggesting that miR-376c is a
negative regulator for PCa progression. Furthermore,
miR-376c is shown to serve as an important regulator
for androgen signaling by targeting the 3′UTR of
UDP-glucuronosyltransferase 2B15 and UGT2B17 in
PCa cells [47]. These studies are similar to our results
showing that the miR-376c expression level is nega-
tively associated with cell migration, invasion, and
PCa progression. Meanwhile, we also showed the first
evidence that miR-376c is essential for the TSP-2-
induced migration in PCa cells. Thus, the modulation
of miR-376c expression may develop as a novel strat-
egy for PCa therapy.
To understand the physiological role of TSP-2 in vivo,
we established a PC-3 cells with stably knockdown of its
TSP-2 (PC-3/shTSP-2-Luc). We found that the expres-
sion of MMP-2, as well as the abilities of migration and
invasion was significantly reduced in PC-3/shTSP-2-Luc
cells, whereas its miR-376c is higher than normal PC-3/
Luc cells. Through monitoring by bioluminescence im-
aging, we showed that the knockdown of TSP-2 dramat-
ically suppresses bone metastasis and osteolytic abilities
of prostate tumor. Interestingly, the tumor with PC-3/
shTSP-2-Luc is smaller than that with PC-3/Luc, al-
though the cell proliferation rates between these cells
are almost the same. We considered that TSP-2 might
(See figure on previous page.)
Fig. 8 The expression of TSP-2 is correlated with Gleason score of PCa and MMP-2 expression. The expression of TSP-2 (a) and miR-376c
(b) between healthy individuals and PCa patients was determined from 52 cases of The Cancer Genome Atlas (TCGA) database. The
correlation of TSP-2 (c) and MMP-2 (d) with PCa progression was determined from 45, 245, 63, 136, and 3 individuals of PCa patients
from the Gleason score 6~10 of TCGA database. The one-way ANOVA with Bonferroni’s multiple comparisons test was performed, and
p ≤ 0.05 showed significance. e The correlation gene expression between TSP-2 and MMP-2 was illustrated from 493 cases of TCGA
database. f The working model represents the roles of TSP-2 on skeletal metastasis of PCa
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regulate osteoclastogenesis and bone remodeling in vivo.
This issue needs further investigation in the future.
The concept of “vicious cycle” has been well estab-
lished in bone metastasis. The tumor-bone interaction
promotes both bone destruction and tumor growth dur-
ing bone metastasis [48]. In the past, the role of MMPs
in tumor progression is focused on invasion and me-
tastasis. However, the crucial role of MMPs in vicious
cycle of bone metastasis has been discussed recently.
MMPs improve the tumor growth not only through
bone destruction but also by regulating bioactivity of
the vicious cycle-related factors such as PTHrP,
RANKL, and TGFβ [49]. Here, our findings reveal
that TSP-2/MMP-2 axis in bone metastasis may be
regulated through complicated mechanism and
remains to be discussed in the future.
Conclusions
In recent years, numerous studies have been addressed
to show the role of TSP-2 in tumor progression as an
anti-angiogenesis by inhibiting cell migration. However,
the role of TSP-2 in PCa has not been examined in
detail. Here, we showed for the first time that TSP-2
plays a positive role in PCa progression. It promotes cell
migration in vitro and in vivo. We also showed that
TSP-2 promotes metastasis by down-regulation of miR-
376c through the MAPK signaling pathway (Fig. 8f ).
This result demonstrates that TSP-2 may represent a
promising new target for treating PCa.
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